Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose. Clinics, [S. l.], v. 78, p. 100150, 2022. DOI: 10.1016/j.clinsp.2022.100150. Disponível em: https://www.journals.usp.br/clinics/article/view/213657.. Acesso em: 9 may. 2024.